Welcome to BC PharmaCare's public survey of drugs being reviewed for coverage. This survey is for bimekizumab (Bimzelx) for the treatment of adult patients with moderate to severe hidradenitis suppurativa (HS) who have inadequate response to conventional systemic therapy.